TR200601092T1 - New oral pharmaceutical formulations containing the active ingredient irbesartan. - Google Patents

New oral pharmaceutical formulations containing the active ingredient irbesartan.

Info

Publication number
TR200601092T1
TR200601092T1 TR2006/01092T TR200601092T TR200601092T1 TR 200601092 T1 TR200601092 T1 TR 200601092T1 TR 2006/01092 T TR2006/01092 T TR 2006/01092T TR 200601092 T TR200601092 T TR 200601092T TR 200601092 T1 TR200601092 T1 TR 200601092T1
Authority
TR
Turkey
Prior art keywords
active ingredient
pharmaceutical formulations
irbesartan
formulations containing
oral pharmaceutical
Prior art date
Application number
TR2006/01092T
Other languages
Turkish (tr)
Inventor
Uslu Abdullah
Original Assignee
Nobel �La� Sanay� Ve T�Caret A�.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nobel �La� Sanay� Ve T�Caret A�. filed Critical Nobel �La� Sanay� Ve T�Caret A�.
Publication of TR200601092T1 publication Critical patent/TR200601092T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Bu buluş irbesartan etken maddesini içeren ve bu etken maddenin oral yolla alınmasını sağlayan yenifarmasötik dozaj formlarını hazırlamak için geliştirilen yeni yöntem ile ilgilidir. Geliştirilen buformülasyon ile irbesartamn dissolüsyon özelliklerine üstünlük kazandırılmıştır.This invention relates to a new method developed for preparing new pharmaceutical dosage forms containing the active ingredient irbesartan and allowing oral administration of this active ingredient. With this developed formulation, the dissolution properties of irbesartan are superior.

TR2006/01092T 2003-09-18 2004-09-16 New oral pharmaceutical formulations containing the active ingredient irbesartan. TR200601092T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2003/01553A TR200301553A1 (en) 2003-09-18 2003-09-18 New oral pharmaceutical formulations containing irbesartan active ingredient

Publications (1)

Publication Number Publication Date
TR200601092T1 true TR200601092T1 (en) 2006-08-21

Family

ID=34311482

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2003/01553A TR200301553A1 (en) 2003-09-18 2003-09-18 New oral pharmaceutical formulations containing irbesartan active ingredient
TR2006/01092T TR200601092T1 (en) 2003-09-18 2004-09-16 New oral pharmaceutical formulations containing the active ingredient irbesartan.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR2003/01553A TR200301553A1 (en) 2003-09-18 2003-09-18 New oral pharmaceutical formulations containing irbesartan active ingredient

Country Status (3)

Country Link
EP (1) EP1670461A1 (en)
TR (2) TR200301553A1 (en)
WO (1) WO2005025566A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1806130E (en) * 2006-01-09 2010-05-11 Krka D D Novo Mesto Solid pharmaceutical composition comprising irbesartan
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
CN101011393B (en) * 2007-02-16 2010-10-06 广州柏赛罗药业有限公司 Irbesartan gastric retention sustained-release pharmaceutical composition
DE102007055341A1 (en) * 2007-11-19 2009-05-20 Bayer Animal Health Gmbh Stabilization of oily suspensions containing hydrophobic silicas
PT2065035E (en) 2007-11-28 2010-10-04 Lesvi Laboratorios Sl Pharmaceutical formulations containing irbesartan
WO2011141783A2 (en) 2010-04-13 2011-11-17 Micro Labs Limited Pharmaceutical composition comprising irbesartan
DE102011108762A1 (en) * 2011-07-28 2013-01-31 Stada Arzneimittel Ag A compressed solid pharmaceutical composition comprising amorphous particulate valsartan as an active ingredient
CN107028912B (en) * 2017-05-31 2019-03-19 珠海润都制药股份有限公司 A kind of preparation method of Irbesartan Capsules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
FR2831446B1 (en) * 2001-10-26 2004-03-05 Sanofi Synthelabo USE OF IRBESARTAN FOR THE PREPARATION OF MEDICINES USEFUL FOR THE PREVENTION OR TREATMENT OF PULMONARY HYPERTENSION
CN1199641C (en) * 2002-10-24 2005-05-04 王登之 Compound irbesartan capsule for curing high blood pressure

Also Published As

Publication number Publication date
WO2005025566A1 (en) 2005-03-24
TR200301553A1 (en) 2005-10-21
EP1670461A1 (en) 2006-06-21

Similar Documents

Publication Publication Date Title
NO20062504L (en) Compositions and dosage forms for improved absorption
CY1112376T1 (en) 2,3,4,9-tetrahydro-1H-carvasol derivative as CRTH2 receptor antagonists
CY1111470T1 (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLYVERSERIN POLYMORPH A
BR0112311A (en) Active agent release compounds and compositions, unit dosage form, method for preparing said compositions and their use
BG66093B1 (en) Controlled release compositions comprising nimesulide
BR0306870A (en) Oral pharmaceutical composition and method for preparing the same
UY27908A1 (en) FORMULATIONS AND DOSAGE FORMS FOR THE CONTROLLED ADMINISTRATION OF TOPIRAMATO
NO20080827L (en) Solid dosage formulations of narcotic drugs that have improved buccal adsorption
CY1113462T1 (en) DOSAGE FORM CONTENTS Pantoprazole as an Active Ingredient
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
SE0401342D0 (en) Therapeutic compounds
ECSP055701A (en) NEW DERIVATIVES OF PYRIMIDINAMIDE AND THE USE OF THE SAME
MXPA05007609A (en) CaSR ANTAGONIST.
DE50203456D1 (en) DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICAMENTS CONTAINING SUCH COMPOUNDS
SE0302573D0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301701D0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301699D0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
TR200601092T1 (en) New oral pharmaceutical formulations containing the active ingredient irbesartan.
SE0302570D0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302572D0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EA200701409A1 (en) NEW COMPOSITION
NO20064808L (en) Oral matrix formulations with licarbazepine
EA200601015A1 (en) ORAL COMPOSITIONS OF DEOXYPEGANINE AND THEIR APPLICATION
CY1106964T1 (en) DRUGS CONTAINING N,N'-DIPERAZINE COMPOUNDS AND THEIR USE
SE0203817D0 (en) New composition